期刊文献+

骨肉瘤肺转移71例生存分析 被引量:17

Survival analysis of 71 cases of osteosarcoma with lung metastases
下载PDF
导出
摘要 目的:分析骨肉瘤肺转移患者的年龄、性别和肺转移灶数目等因素对患者生存的影响。方法:采用多因素回归分析法分析71例骨肉瘤肺转移患者生存相关因素。结果:71例骨肉瘤肺转移患者的2年生存率为38.0%(27/71),中位生存时间20个月;年龄<12岁与≥20岁患者的生存差异有统计学意义(P=0.005);单纯化疗与化疗联合γ刀放射治疗或化疗联合局部手术治疗的生存差异均有统计学意义(P=0.030,P=0.001)。1~2个肺转移灶与>2个肺转移灶的生存差异有统计学意义(P<0.01);初治与复治患者的生存差异无统计学意义(P=0.55)。多因素回归分析显示多学科综合治疗和肺转移灶数目是影响预后的独立因素(P=0.004,P=0.003)。结论:不同转移灶数目对骨肉瘤肺转移的生存时间有影响;多学科综合治疗可改善患者预后。 Objective: To analyze the influence of age, gender, and number of metastases on the survival of osteosarcoma patients with lung metastases. Methods:Survival related factors for 71 osteosarcoma patients with lung metastases were analyzed using the multivariate COX regression analysis. Results:The 2-year survival rate was 38.0% (27/71) and the median survival time was 20 months for the 71 osteosarcoma patients with lung metastases. There were significant differences between patients aging 〈12 years and ≥20 years old (P=0.005). The survival differences were significant between single chemotherapy group and the chemotherapy plus gamma radiation therapy group or chemotherapy combined with local surgery group (P=0.030, P=0.001). The survival difference was significant between patients with 1-2 metastases lesions and those with more than 2 metastases lesions (P〈0.01). There was no significant difference in the survival rate between initially-treated patients with osteosarcoma and secondary treated patients with osteosarcoma (P=0.55). Multivariate regression analysis showed that multi-modality treatment and the number of metastasis lesions were independent prognostic factors (P=0.004, P=0.003). Conclusion: The number of metastatic lesions affected the survival time of osteosarcoma patients with lung metastases. Multi-modality treatment could improve the prognosis of patients.
出处 《肿瘤》 CAS CSCD 北大核心 2009年第5期471-474,共4页 Tumor
基金 上海市科学技术委员会科研计划项目资助项目(编号:064119637)
关键词 骨肉瘤 肿瘤转移 存活率 预后 随访研究 Osteosarcoma, Neoplasm metastasis Survival rate Prognosis Follow-up studies
  • 相关文献

参考文献9

  • 1BENTZEN SM.Prognostic factor studies in oncology:Osteosarcoma as a clinical example[J].Int J Radiat Oncol Biol Phys,2001,49(2):513-518.
  • 2马忠泰,施学东,米川,栗怀广,方志伟.骨源性肉瘤肺转移的手术治疗[J].中华骨科杂志,2003,23(11):668-674. 被引量:5
  • 3赵晖,孙元珏,王建军,林峰,姚阳.以大剂量异环磷酰胺为主的晚期骨肉瘤联合治疗方案[J].肿瘤,2008,28(6):524-527. 被引量:5
  • 4OBATA H,KURATSU S,UCHIDA A.Analysis of organ selecti-vity in the metastatic behavior of Dunn ostosarcoma[J].Clin Orthop Relat Res,2002,5(398):212-222.
  • 5KAGER L,ZOUBEK A,POSTCHGER U,et al.Primary metastatic osteosarcoma:presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols[J].J Clin Oncol,2003,21(10):2011-2018.
  • 6TSUNEMI T,NAGOYA S,KAYA M,et al.Postoperative progression of pulmonary metastasis in osteosarcoma[J].Clin Orthop Relat Res,2003,2(407):159-166.
  • 7TSUCHIYA H,KANAZAWA Y,MOHAMED E,et al.Effect of timing of pulmonary metastases identification on prognosis of patients with osteosarcoma:the Japanese Musculoskeletal Oncology Group study[J].J Clin Oncol,2002,20(16):3470-3477.
  • 8THOMPSON R C Jr,CHENG EY,CLOHISY DR,et al.Results of treatment for metastatic osteosarcoma with neoadjuvant chemotherapy and surgery[J].Clin Orthop Relat Res,2002,4(397):240-247.
  • 9WARD WG,MIKAELIAN K,DOREY F,et al.Pulmonary metastases of stage ⅡB extremity osteosarcoma and subsequent pulmonary metastases[J].J Clin Oncol,1994,12(9):1849-1858.

二级参考文献12

  • 1吴文源.精神症状临床评定量表及其应用[J].诊断学理论与实践,2005,4(4). 被引量:10
  • 2罗扬,冯奉仪,陈平,张湘茹,张德超,王绿化.Ⅱ期和Ⅲ_A期非小细胞肺癌术后生存及复发特点[J].实用肿瘤杂志,2005,20(5):432-434. 被引量:18
  • 3林峰,陶钧,蔡讯,唐晓春,孙元珏,郭跃武,赵晖,姚阳.大剂量甲氨蝶呤联合顺铂治疗骨肉瘤的临床研究[J].临床肿瘤学杂志,2006,11(1):11-14. 被引量:13
  • 4LE DELEY M C, GU1NEBRET1ERE J M, GENTET J C, et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients[J]. Eur J Cancer, 2007,43 (4) :752-761.
  • 5BACCI G, MERCURI M, BRICCOLI A, et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions [J]. Cancer, 1997, 79(2) :245-254.
  • 6ZALUPSKI M M, RANKIN C, RYAN J R, et al. Adjuvant therapy of osteosarcoma-A phase Ⅱ trial: Southwest Oncology Group study 9139[J]. Cancer, 2004, 100(4) : 818-825.
  • 7PATEL S J, LYNCHJW J R, JOHNSON T, et al. Dose-intense inosfamide/doxorubicin/c isplatin based chemotherapy for osteosarcoma in adults [J]. Am J Clin Oncol, 2002, 25 ( 5 ) :489-495.
  • 8BACCI G, BRICCOLI A, ROCCA M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with eisplatin, doxorubiein, and a high dose of methotrexate and ifosfamide[J]. Ann Oncol, 2003, 14(7) :1126-1134.
  • 9CONRMIER J N, PATEL S R, HERZOG C E. Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatmentrelated toxicity in 43 patients with sarcoma[ J]. Cancer, 2001,92 (6) :1550-1555.
  • 10MCVAY J I, WOOD A M. Suspected ifosfamide-induced neurotoxicity[J]. Pharmacotherapy, 1999, 19(12):1450-1455.

共引文献8

同被引文献162

引证文献17

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部